CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISION] CROSS-LICENSE AGREEMENT This Agreement (the "Agreement") is entered into as of October 14, 2002 (the...Cross-License Agreement • October 3rd, 2006 • MetaMorphix Inc. • Pharmaceutical preparations
CROSS LICENSE AGREEMENT between ASTERIAS and BIOTIME and ESICross License Agreement • February 22nd, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • Delaware
This CROSS-LICENSE AGREEMENT (the “Agreement”) is entered into on February 16, 2016 (the “Effective Date”) by and between Asterias Biotherapeutics, Inc., a Delaware corporation, having a place of business at 6300 Dumbarton Circle, Fremont, CA 94555 (“Asterias”), BioTime, Inc., a California corporation, having a place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“BioTime”), and ES Cell International Pte Ltd., a corporation wholly owned by BioTime organized under the laws of Singapore and having a place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“ESI”) (each individually referred to as “Party” and collectively as the “Parties”).
CROSS LICENSE AGREEMENTCross License Agreement • January 28th, 2016 • W R Grace & Co • Chemicals & allied products • New York
GCP Applied Technologies Inc., a corporation organized and existing under the laws of Delaware, USA having an office at 62 Whittemore Ave., Cambridge, MA 02140-1623 (hereinafter referred to as “GCP”);
EX-99.3 4 d443535dex993.htm CROSS LICENSING AGREEMENT CROSS-LICENSE AGREEMENT By and Among ALNYLAM PHARMACEUTICALS, INC. TEKMIRA PHARMACEUTICALS CORPORATION And PROTIVA BIOTHERAPEUTICS INC. Dated: November 12, 2012 EXHIBIT A – IP MANAGEMENT TERMS 42...Cross-License Agreement • May 5th, 2020 • Delaware
This Cross-License Agreement (this “Agreement”) is entered into as of November 12, 2012 (the “Effective Date”), by and among ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A. (“Alnylam”), TEKMIRA PHARMACEUTICALS CORPORATION, a Canadian corporation having a principal office at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), and, solely with respect to Section 10.12, PROTIVA BIOTHERAPEUTICS INC., a wholly-owned subsidiary of Tekmira and a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”).
CROSS LICENSE AGREEMENTCross License Agreement • November 13th, 2006 • Hansen Medical Inc • Orthopedic, prosthetic & surgical appliances & supplies • California
This Cross License Agreement (“Cross License”), dated as of September 1, 2005 (“Effective Date”), is made by and between Intuitive Surgical, Inc., a Delaware corporation having its principal place of business at 950 Kifer Road, Sunnyvale, California 94086, (“ISI”), and Hansen Medical, Inc., a Delaware corporation having its principal place of business at 380 North Bernardo Avenue, Mountain View, California 94043 (“Hansen”). Hansen and ISI may be referred to herein individually as a “Party”, and collectively as the “Parties”.
RECITALCross-License Agreement • April 16th, 2001 • Simplex Solutions Inc • Services-computer programming services • California
AMENDED AND RESTATED CROSS-LICENSE AGREEMENT Between ALNYLAM PHARMACEUTICALS, INC. And PROTIVA BIOTHERAPEUTICS INC. Dated: May 30, 2008Cross-License Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This Amended and Restated Cross-License Agreement (this “Agreement”) is entered into as of May 30, 2008, by and between ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A., and PROTIVA BIOTHERAPEUTICS INC., a Canadian corporation, having a principal office at 100-3480 Gilmore Way, Burnaby, B.C., Canada.
EX-10.26 32 a2216934zex-10_26.htm EX-10.26 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended....Cross-License Agreement • May 5th, 2020 • Delaware
This CROSS-LICENSE AGREEMENT (this “Agreement”) is made as of December 19, 2012 (the “Effective Date”) by and between MEDIMMUNE, LLC a limited liability company organized under the laws of Delaware, U.S.A., having a principal place of business at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”), and XENCOR, INC., a corporation organized under the laws of the state of Delaware, U.S.A, having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016, U.S.A. (“Xencor”).
Intellectual Property Cross License Agreement By and Among Maxygen, Inc. Maxygen Holdings Ltd. Maxygen ApS AND Bayer HealthCare LLC Dated July 1, 2008Cross License Agreement • January 9th, 2009 • Maxygen Inc • Services-commercial physical & biological research • New York
This Intellectual Property Cross License Agreement (this “Agreement”) is made and entered into on this 1st day of July 2008, by and between Maxygen, Inc. (“Maxygen”), a Delaware corporation, Maxygen Holdings Ltd. (“Holdings”), a wholly owned subsidiary of Maxygen and a company organized under the laws of the Cayman Islands, Maxygen ApS, a wholly owned subsidiary of Holdings and a company organized under the laws of the Kingdom of Denmark (“ApS”), and Bayer HealthCare LLC (“Bayer”), a Delaware limited liability company.
CROSS LICENSE AGREEMENTCross License Agreement • October 31st, 2019 • PF2 SpinCo LLC • Services-computer processing & data preparation
This CROSS LICENSE AGREEMENT (this “Agreement”), dated as of March 1, 2017 (the “Closing Date”), is entered into by and among Change Healthcare LLC (f/k/a PF2 NewCo LLC), a Delaware limited liability company (the “NewCo”), eRx Network, LLC, Delaware corporation (“Echo Connect”), and McKesson Corporation, a Delaware Corporation (“MCK”). NewCo, Echo Connect, MCK each may be referred to herein individually as a “Party” and collectively as the “Parties.”
CROSS LICENSE AGREEMENTCross License Agreement • February 4th, 2020 • PF2 SpinCo, Inc. • Services-computer processing & data preparation
This CROSS LICENSE AGREEMENT (this “Agreement”), dated as of March 1, 2017 (the “Closing Date”), is entered into by and among Change Healthcare LLC (f/k/a PF2 NewCo LLC), a Delaware limited liability company (the “NewCo”), eRx Network, LLC, Delaware corporation (“Echo Connect”), and McKesson Corporation, a Delaware Corporation (“MCK”). NewCo, Echo Connect, MCK each may be referred to herein individually as a “Party” and collectively as the “Parties.”
EX-99.3 4 dex993.htm CROSS-LICENSE AGREEMENT B/W PFIZER OVERSEAS PHARMACEUTICALS AND MEDAREX, INC. EXECUTION COPY CROSS-LICENSE AGREEMENTCross-License Agreement • May 5th, 2020
THIS CROSS-LICENSE AGREEMENT (the “Agreement”) is made as of September 15, 2004 (the “Effective Date”) between Pfizer Inc, a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017, and its Affiliates (“Pfizer”), and Medarex, Inc., a New Jersey corporation with a business address at 707 State Road, Princeton, New Jersey 08540 (“Medarex”). Pfizer and Medarex each may be referred to herein individually as a “Party” or collectively as the “Parties.”
CROSS LICENSE AGREEMENTCross License Agreement • August 27th, 2020 • Maxeon Solar Technologies, Ltd. • Semiconductors & related devices
This CROSS LICENSE AGREEMENT (the “Agreement”) has been entered into as of August 26, 2020 (the “Effective Date”) by and between SunPower Corporation (“SPWR”), a Delaware corporation, and Maxeon Solar Pte. Ltd. (“MSSG”), a Singapore corporation. SPWR and MSSG may also be referred to individually as a “Party” or collectively as “Parties.”
CROSS LICENSE AGREEMENTCross License Agreement • April 28th, 2005 • Imcor Pharmaceutical Co • Pharmaceutical preparations • New York
This CROSS LICENSE AGREEMENT (the “Agreement”) is entered into as of the Effective Date, by and between IMCOR Pharmaceutical Co., a Nevada corporation (“IMCOR”), Bristol-Myers Squibb Company, a Delaware corporation (“BMS”), and Bristol-Myers Squibb Medical Imaging, Inc., a Delaware corporation (together with BMS, referred to herein as “BMSMI”). IMCOR and BMSMI may be referred to separately as a “Party” or collectively as the “Parties”.
CROSS LICENSE AGREEMENTCross License Agreement • January 16th, 2008 • Broncus Technologies Inc/Ca • Surgical & medical instruments & apparatus • California
THIS CROSS LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of December 30, 2003 (the “Effective Date”) by and between Broncus Technologies, Inc., a California corporation having its principal place of business at 1400 N. Shoreline Blvd., Bldg. A, Suite 8, Mountain View, California 94303 (“Broncus”) and Asthmatx, Inc., a California corporation having its principal place of business at 1340 Space Park Way, Mountain View, California 94043 (“Asthmatx”).
QUALCOMM and Nortel Sign Cross- License AgreementCross-License Agreement • April 8th, 2021
SAN DIEGO, March 15 /PRNewswire-FirstCall/ -- QUALCOMM Incorporated (Nasdaq: QCOM), a leading developer and innovator of Code Division Multiple Access (CDMA) and other advanced wireless technologies, and Nortel, a leading provider of mobile broadband infrastructure and services, have entered into an agreement which extends and expands the patent and product scope of their previous CDMA cross-license agreement. Under the terms of the agreement, QUALCOMM has granted Nortel a royalty-bearing license under its patent portfolio to manufacture and sell infrastructure products for use in CDMA and GSM wireless networks, and Nortel has granted QUALCOMM a license under its patent portfolio to manufacture and sell components for use in CDMA subscriber devices (including multi-mode CDMA/GSM devices) and infrastructure products. "CDMA" includes CDMA2000(R), WCDMA and TD-SCDMA. The agreement also provides each party with additional patent rights beyond CDMA and GSM, but does not cover Orthogonal Fre
CROSS LICENSE AGREEMENTCross License Agreement • August 24th, 2015 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Cross License Agreement (this “Agreement”) is made as of the Effective Date (as such term is defined below) by and between Asuragen, Inc., a Delaware corporation with its principal offices at 2150 Woodward St., Austin, Texas 78744 (“Asuragen”) and Mirna Therapeutics, Inc., a Delaware corporation with an office at 2150 Woodward Street, Austin, Texas 78744 (“Mirna”); (each of Asuragen and Mirna is referred to herein as “Party” and together as the “Parties”).
FIRST AMENDMENT TO THE CROSS LICENSE AGREEMENTCross License Agreement • August 24th, 2015 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to the Cross License Agreement (the “First Amendment”) is by and between Mirna Therapeutics, Inc. (“Mirna”), a Delaware corporation with a principal business address at 2150 Woodward St., Suite 100, Austin, Texas 78744, and Asuragen, Inc., a Delaware corporation, with a principal business address at 2150 Woodward Street, Austin, Texas 78744 (“Asuragen”), and is effective as of September 28, 2012 (the “First Amendment Effective Date”). All capitalized terms not defined in this First Amendment shall have the meanings given to them in the Cross License Agreement (including Exhibits thereto) entered into by and between Mirna and Asuragen, effective as of November 3, 2009 (the “Agreement”).
CROSS LICENSE AGREEMENTCross License Agreement • September 1st, 2011 • Aspen Aerogels Inc • Wholesale-lumber & other construction materials • Massachusetts
Plaintiff Aspen Aerogels, Inc. and defendant Cabot Corporation, constituting all of the parties who have appeared in this proceeding, hereby stipulate, pursuant to Chancery Court Rule 41(a)(1)(ii), that this action, including any and all claims, counterclaims and defenses asserted herein, is hereby dismissed with prejudice and without costs or attorney’s fees to any party.
CROSS-LICENSE AGREEMENTCross-License Agreement • October 1st, 2021 • Xilio Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Cross-License Agreement (“Agreement”), effective as of December 16, 2020 (the “Effective Date”) and executed on February 11, 2021 (the “Execution Date”), is by and among Xilio Development, Inc., a Delaware corporation with an address at 828 Winter Street, Waltham, MA 02451 (“Xilio”), AskGene Pharma, Inc., a Delaware corporation with an address at 5217 Verdugo Way, Suite A, Camarillo, CA 93012 (“AskGene”) and, solely for purposes of Section 12.8, Xilio Therapeutics, Inc., a Delaware corporation with an address at 828 Winter Street, Waltham, MA 02451 (“Parent”). Xilio and AskGene are referred to herein collectively as the “Parties” and each individually as a “Party.”
CROSS-LICENSE AGREEMENT By and Among ALNYLAM PHARMACEUTICALS, INC. TEKMIRA PHARMACEUTICALS CORPORATION And PROTIVA BIOTHERAPEUTICS INC. Dated: November 12, 2012Cross-License Agreement • March 27th, 2013 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This Cross-License Agreement (this “Agreement”) is entered into as of November 12, 2012 (the “Effective Date”), by and among ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A. (“Alnylam”), TEKMIRA PHARMACEUTICALS CORPORATION, a Canadian corporation having a principal office at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), and, solely with respect to Section 10.12, PROTIVA BIOTHERAPEUTICS INC., a wholly-owned subsidiary of Tekmira and a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”).
EX-10.1 2 dex101.htm CROSS LICENSE AGREEMENT CROSS LICENSE AGREEMENTCross License Agreement • May 5th, 2020 • California
This License Agreement (this “Agreement”) is made effective as of June 30, 2009 (the “Effective Date”) by and among Alphatec Spine, Inc., a Delaware corporation with a principal place of business at 5818 El Camino Real, Carlsbad, California 92008 (“Alphatec”), International Spinal Innovations, LLC, a limited liability company organized under the laws of the state of Connecticut, with an address at 97 Balfour Drive, West Hartford, CT 06117 (“ISI”), and, for purposes of Sections 4.1, 4.4, 7.3, and 11.15 hereof only, Alphatec Holdings, Inc., a Delaware corporation with a principal place of business at 5818 El Camino Real, Carlsbad, California 92008 (“Holdings”). Alphatec and ISI are each hereafter referred to individually as a “Party” and together as the “Parties”.
INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT by and among BORGWARNER INC. and DELPHI TECHNOLOGIES IP LIMITED and PHINIA TECHNOLOGIES, INC. and BORGWARNER LUXEMBOURG OPERATIONS S.A.R.L. Dated as of June 30, 2023Cross-License Agreement • July 7th, 2023 • Phinia Inc. • Motor vehicle parts & accessories
This INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “IP License Agreement”) dated as of June 30, 2023 (“Effective Date”), is by and among BORGWARNER INC., a Delaware corporation (“Parent”), and DELPHI TECHNOLOGIES IP LIMITED, a Barbados limited company, on the one hand, and PHINIA TECHNOLOGIES, INC., a Delaware corporation, and BORGWARNER LUXEMBOURG OPERATIONS S.À.R.L., a Luxembourg société à responsabilité limitée, on the other hand (collectively, the “Parties,” or each, individually, a “Party”).
CROSS LICENSE AGREEMENTCross License Agreement • October 5th, 2006 • Asthmatx Inc • Surgical & medical instruments & apparatus • California
THIS CROSS LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of December 30, 2003 (the “Effective Date”) by and between Broncus Technologies, Inc., a California corporation having its principal place of business at 1400 N. Shoreline Blvd., Bldg. A, Suite 8, Mountain View, California 94303 (“Broncus”) and Asthmatx, Inc., a California corporation having its principal place of business at 1340 Space Park Way, Mountain View, California 94043 (“Asthmatx”).
CROSS-LICENSE AGREEMENTCross-License Agreement • October 1st, 2024 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This CROSS-LICENSE AGREEMENT (this “Agreement”), effective as of September 30, 2024 (the “Effective Date”), is made by and between Seres Therapeutics, Inc., a Delaware corporation (“Seller”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”).
EX-10.6 13 dex106.htm CROSS LICENSE AGREEMENT CROSS LICENSE AGREEMENTCross License Agreement • May 5th, 2020 • California
This CROSS LICENSE AGREEMENT (this “Agreement”) is made and entered into this 14th day of February, 2011, and effective as of February 1, 2010 (the “Effective Date”), by and between Loyalty Alliance Enterprise Corporation, a company organized and existing under the laws of the Cayman Islands and its Affiliates other than PayEase and its subsidiaries (hereinafter referred to as “LA”), and PayEase Corp., a corporation organized and existing under the laws of the State of Delaware and its Affiliates other than LA and its subsidiaries (“PayEase”). LA and PayEase are referred to herein individually each as a “Party” and collectively as the “Parties”.
Certain confidential information contained in this document, marked by [***], has been omitted because Roivant Sciences Ltd. (the “Company”) has determined that the information (i) is not material and (ii) would likely cause competitive harm to the...Cross License Agreement • December 22nd, 2021 • Roivant Sciences Ltd. • Pharmaceutical preparations
This Third Amendment (this “Amendment”) to the Cross License Agreement dated as of April 11, 2018 by and between Genevant Sciences GmbH, a limited liability company organized and existing under the laws of Switzerland (“Company”), a Subsidiary of Genevant Sciences Ltd. (“Genevant”), as assignee of Genevant, and Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus”), as previously amended by two separate amendments each dated as of June 27, 2018 (the “Agreement”), is entered into and made effective as of the date of signature of the later of Company and Arbutus to sign below (the “Third Amendment Effective Date”). Arbutus and Company are sometimes referred to in this Amendment collectively as the “Parties” and individually as a “Party.” Capitalized terms used but not otherwise defined herein have the respective meanings ascribed to such terms in the Agreement.
EX-10.58 4 dex1058.htm CROSS-LICENSE AGREEMENT Confidential Treatment RequestedCross-License Agreement • May 5th, 2020 • New York
Exhibit 10.58 CROSS-LICENSE AGREEMENT This Agreement (“Agreement”) made and entered into as of May 13, 1998 (“Effective Date”), by and between SHIONOGI & CO., LTD., a Japanese corporation having a principal place of business at 1-8, Doshomachi 3-chome, Chuo-Ku, Osaka 541-0045, Japan (“Shionogi”), and SCIOS INC., a Delaware corporation with a principal place of business at 820 West Maude Avenue, Sunnyvale, CA 94085, U.S.A. (“Scios”), WITNESSETH: WHEREAS, Scios owns or controls the patent rights listed on Appendix A (the “Scios Patents Rights”) related to the human protein known as B-type natriuretic peptide (“BNP”); WHEREAS, Shionogi owns or controls the patent rights listed on Appendix B (the “Shionogi Patent Rights”) related to BNP; WHEREAS, as a means to avoid a protracted period of uncertainty due to the opposition of each other’s patent applications and patents around the world, Shionogi and Scios entered into a brief Patent Agreement dated April 28, 1998 (the “April Agreement”) se
CROSS LICENSE AGREEMENTCross License Agreement • March 6th, 2012 • Endologix Inc /De/ • Surgical & medical instruments & apparatus • New Jersey
This CROSS LICENSE AGREEMENT (this “Agreement”) is made effective as of the 26th day of October, 2011 (“Effective Date”), by and between Bard Peripheral Vascular, Inc., an Arizona corporation, with an address at 1415 W. Third Street, Tempe AZ 85281 (“Bard”), and Endologix, Inc., a Delaware corporation, having a principal place of business at 11 Studebaker Irvine, California 92618 (“Endologix”). Bard and Endologix are, collectively, referred to herein as the “Parties,” or, individually, as a “Party.”
CROSS LICENSE AGREEMENT DATED AS OF MARCH 21, 2007 (“AGREEMENT”) BETWEEN APPLICA INCORPORATED (“APPLICA”) AND SALTON, INC. (“SALTON”) BackgroundCross License Agreement • June 28th, 2007 • Salton Inc • Electric housewares & fans • New York
A Applica owns or has the right to use and license certain intellectual property related to the marketing, distribution and sale of portable household appliances.
Amendment to the Cross-License Agreement By and Between MedImmune, LLC and Xencor, Inc.Cross-License Agreement • February 24th, 2021 • Xencor Inc • Pharmaceutical preparations
This amendment ("Amendment") to the license agreement effected December 19, 2012 (the "Agreement") by and between MedImmune, LLC, a limited liability company organized under the laws of Delaware, having a principal place of business at One MedImmune Way, Gaithersburg MD 20878 (“MedImmune”) and Xencor, Inc., a Delaware corporation with an office at 111 W. Lemon Ave., Monrovia, CA 91016 ("Xencor"), is effective as of January 2, 2020. Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Agreement.
EXHIBIT 10.54 PORTIONS OF THIS DOCUMENT INDICATED BY AN [***] HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT OF SUCH INFORMATION. CELLULAR ESSENTIAL PROPERTIES CROSS...Cross License Agreement • August 9th, 2004 • Brightstar Corp.
RECITALSCross-License Agreement • May 14th, 2001 • Caliper Technologies Corp • Laboratory analytical instruments • California
CROSS LICENSE AGREEMENTCross License Agreement • December 29th, 2006 • Sensata Technologies Holland, B.V. • New York
This CROSS LICENSE AGREEMENT (this “Agreement”), dated as of April , 2006 (the “Effective Date”), is entered into by and between Texas Instruments Incorporated, a Delaware corporation (“Seller”), and Sensata Technologies B.V., a Dutch limited liability company, formerly known as Potazia Holding B.V., assignee of S&C Purchase Corp. (“Buyer”) (each a “Party” and collectively, the “Parties”).
CROSS LICENSE AGREEMENT by and between ALIBABA GROUP HOLDING LIMITED and (ANT SMALL AND MICRO FINANCIAL SERVICES GROUP CO., LTD.) Dated as of September 23, 2019Cross License Agreement • November 13th, 2019 • Alibaba Group Holding LTD • Services-business services, nec • New York
This CROSS LICENSE AGREEMENT (the “Agreement”), dated as of September 23, 2019 (the “Effective Date”), is made by and between the following parties (each of which shall be referred to individually as a “Party” and which are referred to collectively as the “Parties”):
